A.R.T. Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

A.R.T. Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,335	Closed	-$56K	–	53
2020 Q4	$56K	Buy	+10,335	New	+$56.1K	0.26%	67
2019 Q2	–	Sell	-24,111	Closed	-$104K	–	1317
2019 Q1	$104K	Buy	+24,111	New	+$112K	0.01%	1167
2018 Q2	–	Sell	-84,925	Closed	-$953K	–	1377
2018 Q1	$953K	Buy	+84,925	New	+$743K	0.04%	683
2017 Q4	–	Sell	-39,158	Closed	-$320K	–	1327
2017 Q3	$320K	Buy	39,158 +15,050	+62%	+$94K	0.02%	984
2017 Q2	$108K	Sell	24,108 -9,665	-29%	-$50.5K	0.01%	1247
2017 Q1	$186K	Buy	+33,773	New	+$148K	0.01%	1175
2016 Q2	–	Sell	-21,600	Closed	-$175K	–	1318
2016 Q1	$175K	Sell	21,600 -400	-2%	-$3.27K	0.01%	1196
2015 Q4	$265K	Buy	+22,000	New	+$215K	0.01%	1100

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

A.R.T. Advisors's ADAP Position: Q1 2021 in Review

A.R.T. Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q1 2021, closing a stake of 10,335 shares — an estimated $56K sold.

A.R.T. Advisors first reported a position in ADAP in Q4 2015 and held it in 8 quarters. The position peaked at $953K in Q1 2018. 84 funds tracked by Wall St. Rank hold ADAP as of Q1 2021.

A.R.T. Advisors reported no remaining Adaptimmune Therapeutics position as of Q1 2021 after selling out during the quarter.
A.R.T. Advisors sold 10,335 Adaptimmune Therapeutics shares in Q1 2021, an estimated $56K.
A.R.T. Advisors first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 8 quarters.
A.R.T. Advisors's Adaptimmune Therapeutics position peaked at $953K in Q1 2018.
84 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2021.

Based on A.R.T. Advisors's 13F filing for Q1 2021, filed 17 May 2021.